Mississippi Universal Preferred Drug List (PDL)
The Mississippi Division of Medicaid (DOM)’s universal preferred drug list (PDL) is for all Medicaid, MississippiCAN (MSCAN) and Children’s Health Insurance Program (CHIP) beneficiaries. Previous PDLs may be found at this link.
- Current PDL: effective October 1, 2024
- Future PDL: effective January 1, 2025
Mississippi Medicaid Preferred Diabetic Supply List (DSL)
- Current DSL: effective July 1, 2024
PDL Change Provider Notices
- PDL Changes Provider Notice: Jan. 1, 2025
MS is a member of the Sovereign States Drug Consortium (SSDC). Change Healthcare negotiates rebate offers on behalf of the SSDC. Drug and diabetic supply manufacturers should refer to information found at this link for the process of submitting rebate offers to the state: Sovereign States Drug Consortium
Important Information for Drug Manufacturers
MedImpact (MI), manages the PDL and administers the Supplemental Rebate Program.
Industry Information Requests
Industry representatives with clinical presentation requests or inquires related to drugs listed on the Preferred Drug List may contact the Division’s clinical contractor, MedImpact (MI). The primary contact at MI for Mississippi Medicaid is:
Dan Inboden, Pharm.D., MBA, PDL and Rebate Strategy Manager
Email: daniel.inboden@medimpact.com
MedImpact
Attn: GPS Medicaid Rebate Operations
10181 Scripps Gateway Ct.
San Diego, CA 92131
PDL Overview
The PDL is a medication list recommended to DOM by the P&T Committee and approved by the executive director of DOM. Drugs designated as preferred have been selected for their efficaciousness, clinical significance, cost effectiveness and safety for Medicaid beneficiaries. The PDL addresses certain drug classes:
- Some drug classes will not be reviewed for preferred status because of no and/or limited cost savings, if the class is all and/or mostly generic, or if there is low utilization in that class.
- Drugs, historically covered by Medicaid and not listed on the PDL, will continue to be covered.
- DOM may opt to include or delete drug classes from PDL review in the future.
New drugs introduced into the marketplace in therapeutic classes that have been reviewed will be considered non-preferred until no later than the annual review of the particular therapeutic class.
- Not reviewed (NR) notation on the PDL document indicates a new drug that has not yet been reviewed by the P&T Committee.
Other items to note on the PDL document:
- Drugs highlighted in yellow, on the PDL document, denote a change in PDL status.
- Preferred brands do not count toward the monthly brand service limit of 2/month. However, preferred brands count toward the drug service limit of 6/month.
- Unless otherwise specified, the listing of a particular brand or generic name includes all dosage forms of that drug.
Preferred Drug List Archive
For more information about past PDLs and provider notices, visit the Preferred Drug List Archive.
